HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline

SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global

WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

WuXi Biologics to Increase Manufacturing Capacity in Germany

WuXi Biologics Again Passed GMP Inspection by Japan PMDA

WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global

WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

SHANGHAI and SAN DIEGO, Jan. 7, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

- WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

- First manufacturing run successful for MFG7 facility at the Ireland site - Largest manufacturing scale to

WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations